Published in Clin Cancer Res on March 03, 2011
OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer (ARMOR1) | NCT00959959
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2012) 5.50
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature (2014) 5.45
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.77
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer (2013) 1.57
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials (2012) 1.48
Enzalutamide for patients with metastatic castration-resistant prostate cancer. Onco Targets Ther (2015) 1.39
Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res (2012) 1.35
Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta (2011) 1.21
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci (2011) 1.11
Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res (2012) 1.10
Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol (2014) 1.08
MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate (2012) 0.97
Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One (2014) 0.96
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab (2013) 0.93
Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget (2014) 0.92
Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol (2012) 0.91
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol (2014) 0.91
AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev (2014) 0.91
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging (2015) 0.90
Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer (2012) 0.90
Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol (2014) 0.89
USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Res (2013) 0.88
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res (2015) 0.83
Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol (2012) 0.81
Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J Transl Med (2013) 0.81
From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int (2014) 0.81
The HIF/PHF8/AR axis promotes prostate cancer progression. Oncogenesis (2016) 0.80
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther (2013) 0.79
Maintenance of androgen receptor inactivation by S-nitrosylation. Cancer Res (2013) 0.78
CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Horm Cancer (2016) 0.78
Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironment. Steroids (2013) 0.77
Establishing prostate cancer patient derived xenografts: lessons learned from older studies. Prostate (2015) 0.77
Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget (2015) 0.77
Arrestin2 modulates androgen receptor activation. Oncogene (2014) 0.76
Maximizing the quantitative accuracy and reproducibility of Förster resonance energy transfer measurement for screening by high throughput widefield microscopy. Methods (2013) 0.76
Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding. BMC Genomics (2012) 0.75
Maximal testosterone suppression in prostate cancer--free vs total testosterone. Urology (2014) 0.75
Genome-wide analysis of androgen receptor binding sites in prostate cancer cells. Exp Ther Med (2015) 0.75
Abiraterone acetate for prostate cancer: a new era of hormonal therapies. Asian J Androl (2011) 0.75
Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity. Nucleic Acids Res (2016) 0.75
Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer. Br J Cancer (2017) 0.75
Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma. Case Rep Med (2014) 0.75
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. Eur J Cancer (2017) 0.75
Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. Oncotarget (2017) 0.75
Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells. Oncotarget (2017) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (2000) 5.03
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol (2008) 3.44
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell (2009) 2.85
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem (2010) 1.97
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res (2009) 1.80
The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol (1991) 1.72
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res (2009) 1.68
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res (2007) 1.67
Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem (1988) 1.60
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate (2010) 1.54
Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol (2010) 1.51
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer (2008) 1.37
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem (2010) 1.36
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol (2009) 1.27
The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am (2001) 1.24
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res (2008) 1.14
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer (2009) 1.04
Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res (2001) 0.99
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell (2009) 2.85
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res (2009) 2.62
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 2.61
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol (2010) 2.47
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab (2011) 2.32
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res (2009) 2.04
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol (2008) 1.85
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin (2011) 1.68
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res (2011) 1.64
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs (2011) 1.53
Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol (2010) 1.51
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol (2009) 1.50
CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res (2008) 1.47
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J (2009) 1.46
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs (2012) 1.38
Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev (2010) 1.34
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer (2010) 1.32
Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol (2013) 1.30
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. Cytometry B Clin Cytom (2010) 1.24
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today (2009) 1.24
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.21
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol (2013) 1.19
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol (2012) 1.19
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res (2010) 1.05
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS One (2013) 1.04
Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol (2012) 1.04
The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. Curr Drug Targets (2011) 1.03
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One (2011) 1.03
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther (2012) 1.01
Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol (2013) 1.01
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res (2013) 0.99
The CT flare response of metastatic bone disease in prostate cancer. Acta Radiol (2011) 0.99
Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther (2010) 0.98
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer (2013) 0.98
Targeting insulin-like growth factor signaling: rational combination strategies. Mol Cancer Ther (2010) 0.97
Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging (2014) 0.97
Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. Histopathology (2014) 0.97
The promise of circulating tumor cell analysis in cancer management. Genome Biol (2014) 0.95
Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor. Mol Cancer Ther (2009) 0.95
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res (2013) 0.95
Belinostat: clinical applications in solid tumors and lymphoma. Expert Opin Investig Drugs (2011) 0.94
FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep (2012) 0.94
Prostate cancer: PSA as an intermediate end point in clinical trials. Nat Rev Urol (2009) 0.92
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets (2011) 0.91
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol (2013) 0.90
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol (2011) 0.89
Molecular pathology and prostate cancer therapeutics: from biology to bedside. J Pathol (2014) 0.88
Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies. Clin Cancer Res (2010) 0.88
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol (2006) 0.87
PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs (2012) 0.87
Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncol (2010) 0.87
Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative--letter. Clin Cancer Res (2011) 0.87
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate (2011) 0.85
Therapeutic options for advanced prostate cancer: 2011 update. Curr Urol Rep (2012) 0.84
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol (2014) 0.82
Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer. Clin Chem (2012) 0.81
A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. Mol Cancer Ther (2007) 0.81
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? EPMA J (2012) 0.81
Novel drugs targeting the androgen receptor pathway in prostate cancer. Cancer Metastasis Rev (2014) 0.81
Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther (2012) 0.80
Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90. Assay Drug Dev Technol (2005) 0.79
Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. Eur J Cancer (2011) 0.79
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2013) 0.78
A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. Prostate (2009) 0.78
What have we learned from exceptional tumour responses?: Review and perspectives. Curr Opin Oncol (2015) 0.78
Revisiting the role of antiandrogen strategies in ovarian cancer. Oncologist (2011) 0.77
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. Clin Cancer Res (2006) 0.77